Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Citi raised the firm’s price target on Insulet to $310 from $283 and keeps a Buy rating on the shares as part of a 2025 outlook for the U.S.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Insulet (PODD – Research Report) today and set a price target of $305.00. The ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...